These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32866691)

  • 1. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
    Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
    Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias.
    Levine YC; Rosenberg MA; Mittleman M; Samuel M; Methachittiphan N; Link M; Josephson ME; Buxton AE
    Heart Rhythm; 2014 Jul; 11(7):1109-16. PubMed ID: 24837348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.
    Arnaldo FJ; Anatoliotakis N; Palacio C; Nabert DR; Hsu SS
    Heart Lung; 2009; 38(1):10-6. PubMed ID: 19150526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs.
    Mordi I; Jhund PS; Gardner RS; Payne J; Carrick D; Berry C; Tzemos N
    JACC Cardiovasc Imaging; 2014 Jun; 7(6):561-9. PubMed ID: 24813968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study.
    Sourour N; Riveland E; Naesgaard P; Kjekshus H; Larsen AI; Omland T; Røsjø H; Myhre PL
    Clin Cardiol; 2023 Aug; 46(8):989-996. PubMed ID: 37400982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT-proBNP and ICD in Nonischemic Systolic Heart Failure: Extended Follow-Up of the DANISH Trial.
    Butt JH; Yafasova A; Elming MB; Dixen U; Nielsen JC; Haarbo J; Videbæk L; Korup E; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Thune JJ; Køber L
    JACC Heart Fail; 2022 Mar; 10(3):161-171. PubMed ID: 35241243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers.
    Scott PA; Townsend PA; Ng LL; Zeb M; Harris S; Roderick PJ; Curzen NP; Morgan JM
    Europace; 2011 Oct; 13(10):1419-27. PubMed ID: 21784745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
    Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
    Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
    Bae MH; Cho Y; Hwang J; Park HS; Han S; Lee YS; Cho HJ; Jung BC; Lee CH; Hyun DW; Park JS; Ahn J; Kim KH; Shin DG
    J Korean Med Sci; 2020 Mar; 35(9):e49. PubMed ID: 32141247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification of Heart Failure Patients With Implantable Cardioverter-Defibrillator.
    Deng Y; Cheng SJ; Hua W; Cai MS; Zhang NX; Niu HX; Chen XH; Gu M; Cai C; Liu X; Huang H; Zhang S
    Front Cardiovasc Med; 2022; 9():823076. PubMed ID: 35299981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose-response meta-analysis.
    Prameswari HS; Putra ICS; Kamarullah W; Pranata R; Iqbal M; Karwiky G; Pramudyo M; Kusumawardhani NY; Achmad C; Martha JW; Akbar MR
    Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy.
    Coats CJ; Gallagher MJ; Foley M; O'Mahony C; Critoph C; Gimeno J; Dawnay A; McKenna WJ; Elliott PM
    Eur Heart J; 2013 Aug; 34(32):2529-37. PubMed ID: 23455360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
    Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
    Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baroreflex sensitivity assessed with the sequence method is associated with ventricular arrhythmias in patients implanted with a defibrillator for the primary prevention of sudden cardiac death.
    Garcia R; Degand B; Fraty M; Le Marcis V; Bidegain N; Laude D; Tavernier M; Le Gal F; Hadjadj S; Saulnier PJ; Ragot S
    Arch Cardiovasc Dis; 2019 Apr; 112(4):270-277. PubMed ID: 30670362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.